Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma
- Friday, December 17, 2021, 7:14
- Business
- Add a comment
TAIPEI and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan…
About the Author
adminasapcorp has written 42001 stories on this site.